Stocks News

LAST PRICE
51.4750
TODAY'S CHANGE (%)
Trending Up0.3750 (0.7339%)

Bid / Lots
51.4500/ 3
Ask / Lots
51.5000/ 6
Open / Previous Close
50.6700 / 51.1000
Day Range
Low 50.6700
High 53.0000
52 Week Range
Low 22.9100
High 66.5400
Volume
414,651
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 29, 2024
- DJ RxSight Initiated at Buy by Jefferies, from 8:01AM ET on Tuesday Oct 29, 2024 by Dow Jones
  8:01AM ET on Tuesday Oct 29, 2024 by Dow Jones
  Companies Mentioned: RXST
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RXST/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 29, 2024 08:01 ET (12:01 GMT)
- Jefferies Initiates RxSight at Buy With $72 Price Target, from 5:57AM ET on Tuesday Oct 29, 2024 by MT Newswires
  5:57AM ET on Tuesday Oct 29, 2024 by MT Newswires
  Companies Mentioned: RXST
  05:57 AM EDT, 10/29/2024 (MT Newswires) -- RxSight (RXST) has an average buy rating and a price target range of $54 to $75, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and...
Oct 24, 2024
- RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024, from 4:05PM ET on Thursday Oct 24, 2024 by Dow Jones
  4:05PM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: RXST
  
  RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
  
  ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Oct 18, 2024
- Rxsight Insider Sold Shares Worth $309,850, According to a Recent SEC Filing, from 5:27PM ET on Friday Oct 18, 2024 by MT Newswires
  5:27PM ET on Friday Oct 18, 2024 by MT Newswires
  Companies Mentioned: RXST
  05:27 PM EDT, 10/18/2024 (MT Newswires) -- Ilya Goldshleger, Co-President and Chief Operating Officer, on October 16, 2024, sold 6,205 shares in Rxsight (RXST) for $309,850. Following the Form 4 filing with the SEC, Goldshleger has control over a to...
Oct 15, 2024
- Rxsight Insider Sold Shares Worth $462,458, According to a Recent SEC Filing, from 4:28PM ET on Tuesday Oct 15, 2024 by MT Newswires
  4:28PM ET on Tuesday Oct 15, 2024 by MT Newswires
  Companies Mentioned: RXST
  04:28 PM EDT, 10/15/2024 (MT Newswires) -- Ilya Goldshleger, Co-President and Chief Operating Officer, on October 10, 2024, sold 9,305 shares in Rxsight (RXST) for $462,458. Following the Form 4 filing with the SEC, Goldshleger has control over a to...

Nov 1, 2024
- DJ Warby Parker Is Maintained at Buy by BTIG, from 3:12PM ET on Friday Nov 01, 2024 by Dow Jones
  3:12PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: WRBY
- DJ 10x Genomics Is Maintained at Overweight by Barclays, from 9:55AM ET on Friday Nov 01, 2024 by Dow Jones
  9:55AM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: TXG
Oct 31, 2024
- DJ Warby Parker Is Maintained at Outperform by Telsey Advisory Group, from 9:53AM ET on Thursday Oct 31, 2024 by Dow Jones
  9:53AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: WRBY
- TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative, from 8:00AM ET on Thursday Oct 31, 2024 by PR Newswire
  8:00AM ET on Thursday Oct 31, 2024 by PR Newswire
  Companies Mentioned: TXG
- TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: TXG
- DJ Novocure Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 5:45AM ET on Thursday Oct 31, 2024 by Dow Jones
  5:45AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: NVCR
Oct 30, 2024
- DJ 10x Genomics Is Maintained at Buy by Citigroup, from 2:43PM ET on Wednesday Oct 30, 2024 by Dow Jones
  2:43PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: TXG
- DJ 10x Genomics Is Maintained at Sell by Goldman Sachs, from 1:10PM ET on Wednesday Oct 30, 2024 by Dow Jones
  1:10PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: TXG
- DJ 10x Genomics Is Maintained at Neutral by JP Morgan, from 12:54PM ET on Wednesday Oct 30, 2024 by Dow Jones
  12:54PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: TXG
- UBS Adjusts Price Target on 10x Genomics to $20 From $25, Maintains Neutral Rating, from 10:55AM ET on Wednesday Oct 30, 2024 by MT Newswires
  10:55AM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: TXG

Rxsight Inc
NASDAQ:RXSTUnited States

Search Criteria

Oct 29, 2024

DJ RxSight Initiated at Buy by Jefferies, from 8:01AM ET on Tuesday Oct 29, 2024 by Dow Jones

Jefferies Initiates RxSight at Buy With $72 Price Target, from 5:57AM ET on Tuesday Oct 29, 2024 by MT Newswires

Oct 24, 2024

RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024, from 4:05PM ET on Thursday Oct 24, 2024 by Dow Jones

Oct 18, 2024

Rxsight Insider Sold Shares Worth $309,850, According to a Recent SEC Filing, from 5:27PM ET on Friday Oct 18, 2024 by MT Newswires

Oct 15, 2024

Rxsight Insider Sold Shares Worth $462,458, According to a Recent SEC Filing, from 4:28PM ET on Tuesday Oct 15, 2024 by MT Newswires

Peers Headlines

Nov 1, 2024

DJ Warby Parker Is Maintained at Buy by BTIG, from 3:12PM ET on Friday Nov 01, 2024 by Dow Jones

DJ 10x Genomics Is Maintained at Overweight by Barclays, from 9:55AM ET on Friday Nov 01, 2024 by Dow Jones

Oct 31, 2024

DJ Warby Parker Is Maintained at Outperform by Telsey Advisory Group, from 9:53AM ET on Thursday Oct 31, 2024 by Dow Jones

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative, from 8:00AM ET on Thursday Oct 31, 2024 by PR Newswire

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones

DJ Novocure Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 5:45AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 30, 2024

DJ 10x Genomics Is Maintained at Buy by Citigroup, from 2:43PM ET on Wednesday Oct 30, 2024 by Dow Jones

DJ 10x Genomics Is Maintained at Sell by Goldman Sachs, from 1:10PM ET on Wednesday Oct 30, 2024 by Dow Jones

DJ 10x Genomics Is Maintained at Neutral by JP Morgan, from 12:54PM ET on Wednesday Oct 30, 2024 by Dow Jones

UBS Adjusts Price Target on 10x Genomics to $20 From $25, Maintains Neutral Rating, from 10:55AM ET on Wednesday Oct 30, 2024 by MT Newswires